NCT02665234

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (actual)
• Sponsor: Mimetogen Pharmaceuticals USA, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.

Conditions

• Keratoconjunctivitis Sicca

Interventions

Type	Name	Description
DRUG	1% Tavilermide Ophthalmic Solution	1% Tavilermide BID Dosing
DRUG	Placebo Ophthalmic Solution	Vehicle Ophthalmic Solution

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-02-01
• Completion: 2017-03-01
• First posted: 2016-01-27
• Last updated: 2019-08-16

Locations

1 site across 1 country: United States